What is the recommended treatment approach for Sjögren’s syndrome?

Treatment of Sjögren's Syndrome

The treatment of Sjögren's syndrome requires a stratified approach based on disease severity and organ involvement: for sicca symptoms, start with artificial tears and oral secretagogues (pilocarpine 5mg four times daily or cevimeline); for moderate-to-severe systemic manifestations including interstitial lung disease, initiate mycophenolate mofetil or azathioprine as first-line steroid-sparing agents; and reserve rituximab for refractory cases or severe organ-threatening disease such as vasculitis, severe pulmonary involvement, or mononeuritis multiplex. 1, 2, 3, 4

Ocular Dryness Management

Mild to Moderate Dry Eye

• Artificial tears remain the cornerstone of initial therapy
• Punctal plugs can be inserted to conserve tears, with silicone plugs preferred as they are removable if epiphora develops (56% retention at 2 years)
• Topical anti-inflammatory therapy with cyclosporine for moderate-to-severe cases
• Autologous serum drops (20%) improve ocular irritation and corneal staining more effectively than artificial tears, particularly in Sjögren's patients 1, 5

Severe Dry Eye

• Oral secretagogues: Pilocarpine 5mg orally four times daily or cevimeline (FDA-approved for Sjögren's dry mouth, with ocular benefits)
  • Pilocarpine improves ability to focus during reading and blurred vision symptoms
  • Cevimeline may have fewer systemic side effects than pilocarpine
  • Common pitfall: Excessive sweating occurs in >40% of patients on pilocarpine; warn patients upfront 1, 5
• Scleral lenses for refractory cases
• Filamentary keratitis: Debride filaments and apply N-acetylcysteine 10% topically 1

Oral Dryness Management

Baseline Assessment Required

Measure whole salivary flow rates before initiating treatment—subjective symptoms don't correlate with objective glandular function 3

Treatment Algorithm

• Mild glandular dysfunction: Non-pharmacological stimulation first

  • Sugar-free acidic candies, lozenges with xylitol
  • Sugar-free chewing gum
  • Preparations should have neutral pH and contain fluoride 3

• Moderate-to-severe dysfunction: Pharmacological secretagogues

  • Pilocarpine 5mg four times daily
  • Cevimeline (preferred for fewer side effects)
  • These show greater improvement in dry mouth than dry eye 1, 5

Systemic Disease Management

Stratification by Severity

Moderate Disease (NYHA II dyspnea, FVC 60-80% predicted, or DLCO 40-70% predicted):

• First-line: Mycophenolate mofetil (MMF) or azathioprine as steroid-sparing agents when long-term immunosuppression is needed 2
• Moderate-dose oral corticosteroids (not exceeding 60mg prednisone daily) with slow taper over weeks-to-months 2
• Monitor: PFTs every 3-6 months, especially in first 1-2 years 2

Severe/High Disease Activity (NYHA III-IV, FVC <60% predicted, or DLCO <40% predicted):

• High-dose corticosteroids initially
• Second-line options if MMF/azathioprine insufficient:
  • Rituximab (preferred for severe manifestations)
  • Calcineurin inhibitors (cyclosporine or tacrolimus) 2

Rapidly Progressive or Acute Respiratory Failure:

• High-dose IV methylprednisolone
• Add rituximab or cyclophosphamide to high-dose steroids
• Critical: Rule out infections or lymphoproliferative disorders first 2

Progressive Fibrotic ILD:

• Nintedanib (FDA-approved antifibrotic) as second-line maintenance therapy, alone or combined with immunomodulatory agents 2

Specific Systemic Manifestations

Inflammatory Arthritis/Musculoskeletal Pain:

• Oral DMARDs following standard rheumatologic protocols
• Short-term moderate-dose glucocorticoids for pain control 4

Vasculitis, Severe Parotid Swelling, Mononeuritis Multiplex:

• Rituximab is the preferred biologic agent 4

Critical Caveat: Avoid TNF inhibitors—they are strongly discouraged for sicca symptoms and most clinical contexts in primary Sjögren's syndrome 4

Key Monitoring Parameters

Drug-Specific Cautions

Azathioprine: Test thiopurine methyltransferase activity/genotype before initiating to prevent life-threatening leukopenia 2

Rituximab: Monitor for hepatitis B reactivation, progressive multifocal leukoencephalopathy, hypogammaglobulinemia, and avoid live vaccines 2

Cyclophosphamide: Provide Pneumocystis jirovecii prophylaxis; use IV route over oral to reduce bladder cancer risk 2

Corticosteroids:

• Short-term risks: glucose intolerance, avascular necrosis, myopathy, psychosis
• Long-term risks: osteoporosis, diabetes, adrenal insufficiency, cataracts 2

Drug-Induced Lung Disease Warning

Medications used to treat Sjögren's can paradoxically cause drug-induced ILD (~1% risk), including methotrexate, leflunomide, rituximab, cyclophosphamide, TNF-alpha inhibitors, and sulfasalazine. Consider this in progressive or refractory patients; may require bronchoscopy, drug withdrawal, and corticosteroids 2

Treatment Sequencing Strategy

The algorithmic approach follows a two-stage regimen:

1. Induction phase: Intensive immunosuppression to restore organ function rapidly
2. Maintenance phase: Sustain therapeutic response with steroid-sparing agents

Practical algorithm:

• No/minimal symptoms → Serial observation without therapy
• Symptomatic with moderate impairment → Moderate-dose corticosteroids + MMF/azathioprine
• Refractory to first-line → Add rituximab or calcineurin inhibitors
• Progressive fibrotic pattern → Add nintedanib
• Rapid progression/respiratory failure → High-dose IV steroids + rituximab or cyclophosphamide → Consider lung transplant evaluation if refractory 2

Multidisciplinary Evaluation Requirements

Patients with moderate-to-severe pain, lack of response to therapy, corneal ulceration, progressive conjunctival scarring, or vision loss should be evaluated by an ophthalmologist 1

For pulmonary manifestations, critical HRCT review with thoracic radiologist in multidisciplinary discussion is essential 2

Suspected lymphoproliferative complications require multidisciplinary review involving rheumatology, pulmonology, pathology, radiology, and hematology/oncology 2